Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
J Immunol ; 153(4): 1449-54, 1994 Aug 15.
Article in English | MEDLINE | ID: mdl-8046224

ABSTRACT

The sequence of activation of the components of the cytokine network subsequent to in vivo application of different dosages of IL-2 is still poorly understood. Although side effects of IL-2 therapy are dose dependent, the dose-response relationship for induction of potentially beneficial or harmful cytokine genes still remains to be studied. We examined the patterns of cytokine gene expression after treatment of chronic hepatitis B patients with various doses of IL-2 in a phase 1 trial. Total RNAs were isolated from PBMC harvested at various time points after s.c. injection of natural IL-2 ranging from 30,000 to 1,000,000 U. Dose-dependent effects on mRNA expression of IL-2, GM-CSF, IFN-gamma, TNF-alpha, and IL-6 were assessed using Northern blotting and slot blotting techniques. A single application of 30,000 U nIL-2 induced selective and long-lasting expression of IL-2, IFN-gamma, and GM-CSF genes, which was not accompanied by accumulation of TNF-alpha and IL-6 mRNAs. Larger dosages of IL-2 induced activation of monokine genes and were associated with systemic side effects. mRNA levels of the different cytokines related to biologic activity and correlated with expression of specific proteins and cellular parameters: IL-2 mRNA with soluble IL-2R serum levels and induction of lymphopenia, GM-CSF mRNA with induction of neutrophilia, and IL-6 mRNA with c-reactive protein serum concentrations. Taken together these data indicate unexpected immunoregulatory activities of very low and nontoxic dosages of IL-2 in vivo.


Subject(s)
Cytokines/metabolism , Interleukin-2/administration & dosage , Adolescent , Adult , Cytokines/genetics , Gene Expression/drug effects , Humans , Lymphocytes/metabolism , Male , Middle Aged , RNA, Messenger/genetics
2.
Ther Immunol ; 1(3): 143-52, 1994 Jun.
Article in English | MEDLINE | ID: mdl-7584490

ABSTRACT

One approach to adoptive cancer immunotherapy is based on the use of bispecific monoclonal antibodies (mAb) capable to redirect ex vivo generated cytolytic T lymphocytes (CTL) onto tumour cells. The efficiency of the CD28 T-cell activation pathway to induce CD3-dependent cytolytic activity was investigated while avoiding modulation of the TCR/CD3 complex needed for targeting by bispecific mAb. When used e.g. in conjunction with anti-CD2 antibodies or diacylglycerol derivatives, the in vitro stimulation of T cells with anti-CD28 mAb resulted within 36 h in high levels of CD3-dependent cytolysis (tested on a FcR+ target in the presence of anti-CD3 mAb) and sustained lymphokine production, such as TNF alpha, IFN gamma and IL-2, which may affect tumour growth when delivered locally by the transferred T cells. Rapid activation may reduce costly in vitro procedures, preserve homing capacities of retransfused T cells, and thus facilitate implementation of clinical trials based on the use of bispecific antibodies.


Subject(s)
CD28 Antigens/immunology , Lymphocyte Activation , T-Lymphocytes, Cytotoxic/immunology , Antibodies, Bispecific/therapeutic use , Antibodies, Monoclonal/immunology , CD3 Complex/immunology , Cells, Cultured , Cytokines/genetics , Cytotoxicity, Immunologic , Diglycerides/pharmacology , Enzyme Activation/drug effects , Gene Expression , Humans , Immunotherapy, Adoptive/methods , Protein Kinase C/metabolism
3.
J Hepatol ; 19(2): 259-67, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8301059

ABSTRACT

Ten patients with chronic hepatitis B received increasing doses of nIL-2 (30,000 U, 100,000 U, 300,000 U, 1.0 million U) subcutaneously in a phase I trial. Each dose was applied once per week over 3 weeks. Serum samples were taken before and 2, 12, 24, 48 and 72 h after the first application of each dose level. Serum concentrations of interleukin-1 (IL-1), IL-2, IL-6, interferon-alfa (IFN-alpha), IFN-gamma, tumor necrosis factor-alpha (TNF-alpha) and GM-CSF as well as the cytokine-dependent serum components neopterin, beta-2-microglobulin (B2M), C-reactive protein (CPR), soluble IL-2-receptor (sIL-2R) and 2'-5'-oligoadenylate synthetase (2-5 OA) were assayed using ELISAs and RIAs. None of the samples tested contained measurable cytokine levels other than IL-2. A low and non-toxic dose of 300,000 U nIL-2 was already biologically active with induction of neopterin, B2M and sIL-2R. Dose-dependent changes peaked 24-48 h after application. The same patients were then enrolled in a phase II trial. Treatment in five of the patients was continued twice per week for 3 months with a biologically active dose of 300,000 U nIL-2 subcutaneously. Two of these patients as well as another five patients from the original group were treated with 1.0 million U nIL-2 subcutaneously, twice weekly for 3 months. Neither a biologically active but non-toxic dose of 300,000 U nIL-2, nor a toxic dose of 1.0 million U resulted in permanent clearance of hepatitis B early antigen (HBeAg).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Adjuvants, Immunologic/therapeutic use , Antiviral Agents/therapeutic use , Hepatitis B/drug therapy , Interleukin-2/therapeutic use , 2',5'-Oligoadenylate Synthetase/blood , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/pharmacokinetics , Adolescent , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacokinetics , Biopterins/analogs & derivatives , Biopterins/blood , C-Reactive Protein/analysis , Chronic Disease , DNA, Viral/analysis , DNA, Viral/genetics , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Granulocyte-Macrophage Colony-Stimulating Factor/blood , Hepatitis B/blood , Hepatitis B/immunology , Hepatitis B e Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis B virus/physiology , Humans , Injections, Subcutaneous , Interferon-gamma/blood , Interleukin-1/blood , Interleukin-2/administration & dosage , Interleukin-2/pharmacokinetics , Male , Middle Aged , Neopterin , Pilot Projects , Radioimmunoassay , Receptors, Interleukin-2/analysis , Time Factors , Tumor Necrosis Factor-alpha/analysis , Virus Replication , beta 2-Microglobulin/analysis
5.
Clin Exp Immunol ; 80(2): 241-6, 1990 May.
Article in English | MEDLINE | ID: mdl-2357852

ABSTRACT

A role for naturally occurring cytotoxic cells in immunosurveillance against malignancy has been presumed in several studies. The natural killer activity (NKA) of peripheral blood mononuclear cells was therefore measured at regular intervals in patients with acute leukaemia and expressed specific cytotoxicity. Sixty controls had a median NKA of 33.6% (range 15.4-71). Seventy-three patients with acute lymphoblastic leukaemia (ALL) and acute non-lymphoblastic leukaemia (ANLL) with untreated or relapsed disease had a median activity of 2.4% (range 0-13.4) (P less than 0.001), while 57 patients who had achieved complete remission had a median activity of 22.7% (range 9.5-64.4). In 15 patients, reductions of NKA were seen prior to 16 episodes of relapse. In ten of these (nine with ANLL and one with ALL), 11 relapses were preceded within 10 weeks by drops in NKA to less than 30% of remission levels. The median NKA of the group prior to the drop in activity was 25.5% and the median first low value was 6.0%. Five patients who relapsed after allogeneic bone marrow transplantation had significant, sustained drops in NKA, 5-9 weeks earlier. The median NKA prior to the drop was 25.6% and the median first low value was 8.0%. We therefore conclude that there was a marked reduction in NKA in patients with active acute leukaemia when compared with healthy blood donors and that this activity substantially improved in complete remission. All patients who relapsed had significantly reduced NKA which in some, significantly preceded the time of relapse. These data suggest that the regular assessment of NKA in patients with acute leukaemia may be a useful diagnostic tool.


Subject(s)
Killer Cells, Natural/immunology , Leukemia, Myeloid, Acute/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Adolescent , Adult , Aged , Cytotoxicity Tests, Immunologic , Female , Humans , Male , Middle Aged , Recurrence
6.
Clin Exp Immunol ; 80(1): 94-9, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2323104

ABSTRACT

While the sensitivity of cell lines and solid tumours to lymphokine-activated killer (LAK) cell cytotoxicity is extensively reported, the ability of these generated cytotoxic cells to lyse leukaemic blast cells is controversial. This study reports the successful generation of LAK cells with specificity for leukaemic blast cells. Control donors, patients in remission and patients with active leukaemia were capable of lysing allogeneic leukaemic blast cells. One patient was also capable of lysing autologous leukaemic blast cells. Successful LAK generation was achieved by the use of high dose recombinant interleukin-2 (rIL-2) while combinations of lymphokines did not improve LAK specificity or efficacy. These findings suggest that LAK immunotherapy may be considered for the treatment of patients with acute leukaemia.


Subject(s)
Cytotoxicity, Immunologic , Killer Cells, Lymphokine-Activated/immunology , Leukemia, Myeloid, Acute/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Adolescent , Adult , Aged , Cytotoxicity Tests, Immunologic , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...